REG - Nuformix PLC - Total Voting Rights

NuformixAnnouncement

29/11/2024 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241129:nRSc2467Oa&default-theme=true

RNS Number : 2467O  Nuformix PLC  29 November 2024

29 November 2024

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Total Voting Rights

 

Following the issue of new ordinary shares of 0.05p each in the Company
("Ordinary Shares"), as announced on 4 November 2024, the Company is today
providing a confirmation regarding its voting rights, in line with section DTR
5.6.1 of the FCA's Disclosure Guidance and Transparency Rules sourcebook.

 

As of the date of this announcement, the Company's issued ordinary share
capital consists of 1,419,309,368 Ordinary Shares, each with one voting
right.  The Company does not hold any Ordinary Shares in treasury.  The
total voting rights figure is therefore 1,419,309,368 and this can be used by
shareholders as the denominator for the calculations by which they will
determine whether they are required to notify their interest in, or a change
of their interest in, the Company under the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority.

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRUKVVRSVUAUAA